MCP AL retard

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of MCP AL retard

Property Description
Active ingredient Metoclopramide
Form Sustained-release hard capsule (Retard)
Pharmacological class Prokinetic agent, Miscellaneous antiemetic
Common use Relieving nausea, vomiting, and gastric motility issues
Origin Synthetic compound

What is the Composition and Class of MCP AL retard?

MCP AL retard is a prescription-only pharmaceutical preparation whose sole active ingredient is the synthetic compound Metoclopramide. Pharmacologically, Metoclopramide is classified as a prokinetic agent and a miscellaneous antiemetic. This classification means the medicine is designed to enhance the physical movement, or motility, within the digestive tract, a function intended for promoting the transit of contents through the upper digestive system. Metoclopramide is primarily a dopamine receptor antagonist, a core mechanism that facilitates both improved digestive function and control over the urge to vomit.


Why is it a "Retard" Sustained-Release Capsule?

The term "retard" defines this specific oral formulation as a sustained-release hard capsule, which is a specialized design intended to deliver the Metoclopramide slowly into the body over an extended period. This mechanism ensures prolonged therapeutic action, a distinguishing feature compared to immediate-release tablets where the active ingredient is absorbed quickly. The sustained-release characteristic is achieved through specific excipients that control the drug’s dissolution rate, maintaining a stable, effective concentration of the medicine in the bloodstream. This stable delivery over time is crucial for patients requiring consistent symptom management throughout the day.


What is the General Purpose of This Prokinetic Agent?

The general purpose of MCP AL retard is to leverage the dual physiological action of Metoclopramide: enhancing gastric movement and suppressing the urge to feel sick. It functions by promoting rhythmic contractions (peristalsis) of the stomach, accelerating the rate of gastric emptying. Concurrently, its anti-emetic effect works centrally by modulating signals that trigger the reflexes of nausea and vomiting. These combined mechanisms allow the medication to generally help relieve common discomforts associated with irregular or slow movement in the upper digestive system, often seen in conditions like diabetic gastroparesis, by normalizing transit and suppressing the feeling of sickness.

Regulatory References

  1. NIH StatPearls: Metoclopramide
Advertisements

What side effects are possible with MCP AL retard?

Possible side effects and safety information

Metoclopramide, the active ingredient in MCP AL retard, is associated with a risk profile largely defined by its effects on the central and peripheral nervous systems, as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

The adverse reactions documented in the official safety profile are classified by frequency, with the most common effects often involving the Nervous System and Gastrointestinal System:

Classification Examples of Documented Reactions
Common Somnolence (drowsiness), headache, diarrhea, asthenia (fatigue)
Uncommon Bradycardia (slow heart rate), Extrapyramidal Disorders (e.g., dystonia), hypotension
Rare Convulsion (seizure), confusional state, hallucination
Not Known Neuroleptic Malignant Syndrome (NMS), Cardiac arrest, Tardive Dyskinesia (TD)

Serious and Time-Related Safety Considerations

Official regulatory documents emphasize the risk of Tardive Dyskinesia (TD), a potentially irreversible involuntary movement disorder, which is explicitly linked to long-term exposure (generally treatment exceeding 12 weeks). Acute Extrapyramidal Reactions are documented as occurring more frequently at the start of treatment and are also a consideration for children and young adults.

The regulatory safety profile also notes serious events such as Neuroleptic Malignant Syndrome (NMS) and the potential for Cardiac Arrest.

Safety limitations restrict use in patients with pre-existing conditions such as epilepsy (due to risk of increased seizure frequency) and in cases of gastrointestinal hemorrhage, obstruction, or perforation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the manifestations of Metoclopramide overdose and the emergency actions mandated by regulatory authorities, based strictly on official prescribing information.

Overdose Scope Official Regulatory Information
Documented Manifestations Symptoms include drowsiness, confusion, seizures, and lack of energy. A critical manifestation is the occurrence of extrapyramidal reactions (involuntary movement disorders) [NIH MedlinePlus].
Physiological Systems Documented effects involve the Central Nervous System and the Cardiovascular System. Severe outcomes reported include cardiac arrest, circulatory collapse, and severe bradycardia [EMA Safety Review].
Population-Specific Note Unintentional overdose in infants and children has been documented, with specific risks including methemoglobinemia, seizures, and extrapyramidal reactions [FDA Prescribing Information].
Immediate Help Required Emergency services must be called immediately if overdose results in seizures, trouble breathing, uncontrollable movements, or if the patient cannot be awakened. Immediate medical attention is also required if any extrapyramidal symptoms are noticed [NIH MedlinePlus].
Overdose Management Official Regulatory Guidance
Antidote Status No specific antidote is known for Metoclopramide overdose [FDA Prescribing Information].
Supportive Treatment Management is primarily symptomatic and supportive. Treatment for extrapyramidal reactions is documented to involve anticholinergic or antiparkinsonian medicinal products [FDA Prescribing Information].

The official overdose profile is defined by these critical CNS and cardiovascular manifestations that require urgent medical intervention. This approach explicitly mandates seeking immediate help for severe signs like seizures or extrapyramidal symptoms, while management is directed toward supportive care due to the documented lack of a specific antidote.

Advertisements

Therapeutic Uses of MCP AL retard

What MCP AL retard treats: main uses and benefits

MCP AL retard is a medication containing metoclopramide, which belongs to the class of dopamine antagonists. It acts primarily by influencing the motility of the upper gastrointestinal tract and affecting the brain's vomiting center.

Main Uses

The medication is used to manage various conditions related to the digestive system, specifically focusing on movement disorders and nausea.

  • Symptomatic Treatment of Motility Disorders: It is used to treat impaired movement in the upper gastrointestinal tract. This includes conditions where the stomach does not empty quickly enough, often leading to symptoms such as bloating and early satiety.
  • Nausea and Vomiting: The active ingredient is effective in suppressing the urge to vomit and reducing nausea. This includes the management of nausea induced by certain medications or conditions that disrupt digestive balance.
  • Gastroparesis: It is utilized to improve gastric emptying in cases where the stomach muscles are weakened or not functioning properly.

Benefits and Mechanism of Action

The primary benefit of MCP AL retard is its ability to restore more natural movement to the digestive system while providing relief from distressing gastric symptoms.

  • Prokinetic Effect: By increasing the contractions of the stomach and small intestine, the medication helps move food through the digestive tract more efficiently. This helps prevent the stagnation of gastric contents.
  • Central Action: The medication crosses the blood-brain barrier to inhibit dopamine receptors in the chemoreceptor trigger zone. This action blocks the signals that trigger the vomiting reflex, providing relief from nausea.
  • Sustained Release: As a "retard" formulation, the medication is designed to release the active substance over a longer period. This allows for a more consistent level of the drug in the bloodstream, which can lead to prolonged symptom control compared to immediate-release versions.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use MCP AL retard

Official regulatory guidelines define strict rules for the use of Metoclopramide sustained-release. The medicine is primarily for adults and its use is strictly time-limited (e.g., up to 12 weeks for chronic conditions, with shorter limits in other regions).

Absolute Contraindications (Must Not Use):

Metoclopramide is formally contraindicated for populations with specific medical conditions. These include patients with known or suspected Pheochromocytoma, a history of Tardive Dyskinesia, Parkinson’s disease, or Epilepsy. It must not be used when gastrointestinal motility is dangerous, such as with GI hemorrhage, obstruction, or perforation. Use is also prohibited in patients taking Levodopa or dopaminergic agonists and in children under 1 year of age.

Restricted and Conditional Use:

Certain populations may only use the medicine under restricted conditions. Patients with moderate to severe renal impairment or severe hepatic impairment require a dose reduction. In older adults, a lower starting dosage and careful monitoring are necessary. Use during pregnancy is generally discouraged unless clearly needed, and it is not recommended while breastfeeding, as the medicine is excreted in milk.

Advertisements

What should I know about interactions with other medicines?

The active substance in MCP AL retard is metoclopramide, a medication that can interact with various other medicines and substances. It is essential to inform your doctor or pharmacist about all prescription, over-the-counter drugs, and supplements you are taking to prevent potentially harmful interactions.

Do not take MCP AL retard with the following substances:

  • Levodopa and other Dopaminergic Agonists: Metoclopramide can inhibit the effects of these medications, which are often used to treat Parkinson's disease, as they act in opposition to each other's mechanisms.

Interactions requiring caution and monitoring:

Type of Interacting Agent Potential Effect Action Recommended
Central Nervous System (CNS) Depressants (e.g., Opioids, Benzodiazepines, Alcohol, Sedative Antihistamines) Increased sedation, drowsiness, dizziness, and central side effects. Use with caution; monitor for increased CNS depression. Avoid alcohol.
Anticholinergic Agents and Antidiarrheal Drugs (e.g., Loperamide) Decreased efficacy of metoclopramide due to opposing effects on gut motility. Avoid co-administration if possible.
Antipsychotics and other Dopamine Antagonists (e.g., Haloperidol, Aripiprazole) Increased risk of extrapyramidal symptoms (involuntary movement disorders). Monitor closely for movement problems. Avoid combination if symptoms develop.
Digoxin or Cyclosporine Metoclopramide can affect the absorption of these drugs (decreasing Digoxin, increasing Cyclosporine). Close monitoring of blood levels for the interacting drug may be necessary.

Metoclopramide can also affect insulin requirements in diabetic patients due to its effect on gastric emptying. Insulin dosage may need adjustment, and blood glucose levels should be monitored more frequently.

Advertisements

Mechanism of Action

The active ingredient, metoclopramide, exerts its action through modulation of multiple neurochemical pathways in both the central and peripheral nervous systems.

Dopamine Receptor Antagonism

This mechanism involves the competitive blocking of dopamine D2 receptors located in the chemoreceptor trigger zone (CTZ) of the central nervous system. This molecular interaction suppresses the signaling sequences mediated by dopaminergic neurotransmission, thereby modulating the activity of the CTZ.

Serotonin Receptor Modulation

In the enteric nervous system, the compound engages in a dual interaction by acting as an agonist on 5-HT4 (serotonin) receptors and an antagonist on 5-HT3 receptors. This integrated receptor engagement promotes the release of acetylcholine from intrinsic cholinergic neurons.

Gastrointestinal Prokinetic Effect

This sequence of peripheral cholinergic enhancement increases the basal tone of the lower esophageal sphincter and enhances the force and frequency of contractions in the gastric and intestinal smooth musculature. This overall modulation of peristaltic function constitutes the systemic physiological consequence of the drug's action.

Advertisements

Dosage and Administration Information

How to Use MCP AL retard

This section outlines the standardized administration protocol for Metoclopramide 15 mg prolonged-release capsules.


Administration Guidelines

Property Official Instruction
Route of Administration The approved route is oral, consistent with the capsule form.
Standard Dosing The typical dose for adults is 15 mg; the maximum recommended total daily dose should not exceed 30 mg.
Frequency & Timing The prolonged-release capsule is generally taken once daily. It is typically administered 30 minutes before a meal to correlate with digestive tract activity.
Course Duration The duration of treatment is restricted to short-term use only, with most regimens limited to a maximum of 5 consecutive days.

Procedural Requirements

Administration of this formulation requires specific procedural steps to ensure the intended therapeutic profile. The sustained-release capsule must be swallowed whole and must not be crushed, chewed, or divided. This procedural constraint is essential to maintain the retard characteristic, which controls the release of the active ingredient over an extended period. In cases where a dose is missed, a minimum interval of 6 hours between administrations must be respected, and a double dose should not be taken.

Dose reduction is a required adjustment for patients with confirmed renal impairment or severe hepatic impairment, standardizing the use of the medicine across these specific physiological conditions.

Advertisements

Recent Clinical Evidence

Evidence for Use in Treating Nausea and Vomiting

Research has evaluated MCP AL retard (metoclopramide) in settings where patients experience nausea and vomiting, which are outcomes related to physical discomfort. Various study types have been used in research exploring how symptoms change over time, specifically exploring the role of MCP AL retard in patients experiencing nausea and vomiting related to various conditions. The findings describe patterns observed in the studies where patients reported how their symptoms evolved. However, evidence quality varies across studies, and the findings were mixed on certain measures. What is still uncertain is how results might differ across all various causes of nausea and vomiting, and the certainty remains low for predicting an individual's specific outcome.


Evidence for Use in Managing Stomach Emptying Issues (Gastroparesis)

MCP AL retard was evaluated in patients with gastroparesis, a condition marked by functional limitations related to delayed stomach emptying. Studies monitored outcomes related to systemic or functional imbalance using objective measures and patient-reported outcomes describing perceived discomfort. The research exploring short-term symptom changes reported that findings describe patterns observed in the studies that contribute to understanding symptom patterns in this population. Crucially, data for certain groups remain insufficient, meaning more research is needed to fully characterize the observed patterns in all patients with gastroparesis.


Long-Term Studies and Follow-up

Research has also explored the need for continuous or long-term observation of symptoms, which may be relevant for conditions involving periods of heightened symptoms. The available long-term studies and follow-up data often derive from observational settings rather than exclusively from clinical trials. However, the long-term effects are not fully established. Follow-up durations were limited in many controlled studies, meaning there is limited information for long-term outcomes regarding the effects of MCP AL retard. The evidence contributes to the broader evidence landscape, but the certainty remains low regarding very extended observation periods.


Evidence in Special Populations

Research examined MCP AL retard in patients with comorbid conditions and other specific groups, known as special populations. Studies evaluating children and older adults are sometimes conducted, but data for certain groups remain insufficient. For instance, evidence for patients with complex comorbid conditions is often found in small studies. The subgroup findings are uncertain due to the fact that sample sizes were modest in many of these specialized areas of research. Therefore, the results apply only to the populations studied.


What is Still Uncertain About MCP AL Retard

The research and evidence gathered so far highlights what is known — and what is still uncertain. MCP AL retard was associated with certain patterns of changes in symptoms, as seen in the research, but there are acknowledged research limitation frames. One area of uncertainty relates to the long-term patterns, as follow-up durations were limited, and there is limited information for long-term outcomes. Furthermore, comparative evidence is lacking in certain symptom areas. Researchers continue to note that the evidence quality varies across studies and that research is ongoing to provide greater clarity on the full range of observed patterns.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about MCP AL retard (FAQ)


Q: Can this drug be taken by people who drive?

A: Official product information notes that metoclopramide can cause drowsiness and dizziness, and may affect your vision or concentration. Official guidance suggests avoiding driving or operating machinery until the effects of the medicine on the individual are known.

Q: Are there any foods or drinks that should be avoided when taking this?

A: Regulatory documents advise that alcohol should be avoided while using this medication, as it may increase central side effects like drowsiness. Beyond alcohol, specific restrictions against particular foods or non-alcoholic drinks are generally not listed in the official labeling.

Q: Is it common to feel a little dizzy after taking MCP AL retard?

A: Official product summaries indicate that dizziness is a documented side effect, often listed as a common reaction in some regulatory documents. This effect may be more noticeable when the medicine is first administered or when combined with other substances that also cause sedation.

Q: Is a feeling of restlessness a possible side effect?

A: A feeling of restlessness, medically known as akathisia, is a reported adverse reaction associated with this medication. Restlessness falls under the category of extrapyramidal disorders, which are involuntary movement problems that have been documented with metoclopramide use.

Q: Is it normal to feel a change in mood while using it?

A: Official warnings mention that side effects can include changes in mental state, such as confusion, hallucination, and even depression or thoughts about suicide. Official information suggests that patients be aware of any significant changes in mood or behavior while taking this medication.

Q: Why is the drug sometimes prescribed for migraines?

A: The drug is officially indicated for the symptomatic treatment of nausea and vomiting, which are symptoms often experienced during an acute migraine. Additionally, regulatory information notes it may be used along with oral pain relievers to help improve their absorption.

Q: Are there any specific laboratory tests required while taking this?

A: Routine laboratory tests are not generally listed as a requirement for all patients in regulatory documents. However, if the medication is used alongside certain other drugs, such as Digoxin or Cyclosporine, close monitoring of those drug's blood levels may be necessary according to official documentation.

Q: Does MCP AL retard interact with medications for depression or anxiety?

A: Caution is advised when combining metoclopramide with medications that affect serotonin levels, such as certain antidepressants (serotonergic drugs). Official information indicates this combination may increase the risk of a serious condition called Serotonin Syndrome, and monitoring may be necessary.

Q: Can I take this medication if I have a heart condition?

A: Official safety information notes that this drug has been associated with changes in heart rhythm, including bradycardia (slow heart rate) and, rarely, cardiac arrest. Due to the potential for the drug to affect heart rhythm, individuals with a history of heart problems are advised to discuss this with a healthcare professional.

Q: Does taking this drug affect one's ability to concentrate?

A: Side effects such as drowsiness (somnolence) and confusion are documented in official safety profiles. These effects may impact mental clarity, alertness, and one's ability to concentrate while using the medicine.

Q: Is it true that this drug has a 'black box' warning in some countries?

A: In certain regions, such as the United States, the regulatory authority has placed a Black Box Warning on metoclopramide products. This warning highlights the risk of developing Tardive Dyskinesia (an involuntary movement disorder) with long-term or high-dose use.

Q: Does MCP AL retard contain lactose or gluten?

A: Official product information states that the tablet formulation contains lactose. Individuals with certain hereditary sugar intolerances are advised to consult official documentation. Regulatory documents do not specifically list the presence or absence of gluten.

Advertisements

How should MCP AL retard be stored and disposed of?

How to Store and Dispose of MCP AL retard?

Strict adherence to official labeling ensures product stability and safety, as documented by regulatory agencies.

Storage Requirements

Condition Requirement
Temperature Do not store above 25 C
Protection Keep in the original packaging to protect the contents from light.
Child Safety Keep out of the sight and reach of children.
Handling Avoid prolonged exposure to direct sunlight for capsules removed from the packaging.

Disposal Instructions

  • Do not dispose of the medicinal product via wastewater or household waste.
  • Disposal of the product or waste material must be done in accordance with local requirements for pharmaceutical waste.
  • This approach, documented in official sources, is intended to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of MCP AL retard found in:

A-Z Index: